At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 87 enrolled
Drug / intervention
INCAGN01949drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
In Brief
A Phase 2 clinical trial evaluating INCAGN01949 for Advanced Malignancies and Metastatic Cancer. Completed, enrolled 87 participants across 8 sites in 4 countries.
Detailed Summary
The purpose of this study is to determine the safety and tolerability and assess preliminary efficacy of INCAGN01949 in subjects with advanced or metastatic solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignancies, Metastatic Cancer
CountriesSpain, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartOct 2016
Primary CompletionMar 2019
TodayJul 2026
First PostedOct 4, 2016
Enrollment StartOct 31, 2016
Primary CompletionMar 26, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.7 years ago
Interventions
INCAGN01949drug
Initial cohort dose of INCAGN01949 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.